These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 34028386)

  • 21. Humoral response to heterologous prime-booster vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine.
    Tanner R; Starr N; Perez-Garcia CN; Chan G; Dempsey E; Heffernan E; Lynch B; Hannan MM; Joyce E
    Transpl Infect Dis; 2022 Dec; 24(6):e13935. PubMed ID: 35980217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients.
    Hallett AM; Greenberg RS; Boyarsky BJ; Shah PD; Ou MT; Teles AT; Krach MR; López JI; Werbel WA; Avery RK; Bae S; Tobian AA; Massie AB; Higgins RSD; Garonzik-Wang JM; Segev DL; Bush EL
    J Heart Lung Transplant; 2021 Dec; 40(12):1579-1588. PubMed ID: 34456108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Response Post-SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept.
    Noble J; Langello A; Bouchut W; Lupo J; Lombardo D; Rostaing L
    Transplantation; 2021 Nov; 105(11):e259-e260. PubMed ID: 34387243
    [No Abstract]   [Full Text] [Related]  

  • 24. Control of Humoral Response in Renal Transplantation by Belatacept Depends on a Direct Effect on B Cells and Impaired T Follicular Helper-B Cell Crosstalk.
    Leibler C; Thiolat A; Hénique C; Samson C; Pilon C; Tamagne M; Pirenne F; Vingert B; Cohen JL; Grimbert P
    J Am Soc Nephrol; 2018 Mar; 29(3):1049-1062. PubMed ID: 29321143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine.
    Abravanel F; Marion O; Del Bello A; Beunon T; Romieu-Mourez R; Couat C; Pucelle M; Staes L; Guitard J; Esposito L; Faguer S; Kamar N; Izopet J
    Vaccines (Basel); 2022 Feb; 10(3):. PubMed ID: 35334985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low Performance of Sinovac Vaccine Particularly With Belatacept Therapy in a Study With Different Types of COVID-19 Vaccines in Transplanted Patients.
    Arias-Murillo YR; Salinas-Nova MA; Caicedo T; Galindo-Borda M; Meneses-Gil X; Montero C; Giron F; Pedraza N; Aroca G; Ospina-Martinez ML; Mercado-Reyes M
    Transplant Proc; 2023 Apr; 55(3):500-507. PubMed ID: 36997378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-SARS-CoV-2 T-cell Responses After mRNA Vaccination in Belatacept-treated Renal Transplant Patients.
    Dolff S; Korth J; Jahn M; Kribben A; Witzke O; Wilde B
    Transplantation; 2021 Sep; 105(9):e99. PubMed ID: 33966023
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
    Wojciechowski D; Chandran S; Vincenti F
    Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.
    Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
    Am J Transplant; 2018 Jul; 18(7):1783-1789. PubMed ID: 29509295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?
    Rodriguez-Cubillo B; de la Higuera MAM; Lucena R; Franci EV; Hurtado M; Romero NC; Moreno AR; Valencia D; Velo M; Fornie IS; Sanchez-Fructuoso AI
    Am J Transplant; 2020 Nov; 20(11):3173-3181. PubMed ID: 32529737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood unconjugated bilirubin and tacrolimus are negative predictors of specific cellular immunity in kidney transplant recipients after SAR-CoV-2 inactivated vaccination.
    Zhang L; Yang J; Deng M; Xu C; Lai C; Deng X; Wang Y; Zhou Q; Liu Y; Wan L; Li P; Fang J; Hou J; Lai X; Ma F; Li N; Li G; Kong W; Zhang W; Li J; Cao M; Feng L; Chen Z; Chen L; Ji T
    Sci Rep; 2023 May; 13(1):7263. PubMed ID: 37142713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney transplant recipients treated with belatacept exhibit increased naïve and transitional B cells.
    Leibler C; Matignon M; Pilon C; Montespan F; Bigot J; Lang P; Carosella ED; Cohen J; Rouas-Freiss N; Grimbert P; Menier C
    Am J Transplant; 2014 May; 14(5):1173-82. PubMed ID: 24730563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys.
    Song L; Ma A; Dun H; Hu Y; Fujii Y; Kinugasa F; Oshima S; Higashi Y; Daloze P; Chen H
    Am J Transplant; 2017 Mar; 17(3):635-645. PubMed ID: 27598231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept.
    Chavarot N; Ouedrani A; Marion O; Leruez-Ville M; Vilain E; Baaziz M; Del Bello A; Burger C; Sberro-Soussan R; Martinez F; Chatenoud L; Abravanel F; Anglicheau D; Izopet J; Couat C; Zuber J; Legendre C; Lanternier F; Kamar N; Scemla A
    Transplantation; 2021 Sep; 105(9):e94-e95. PubMed ID: 33831941
    [No Abstract]   [Full Text] [Related]  

  • 36. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT.
    Florman S; Vincenti F; Durrbach A; Abouljoud M; Bresnahan B; Garcia VD; Mulloy L; Rice K; Rostaing L; Zayas C; Calderon K; Meier-Kriesche U; Polinsky M; Yang L; Medina Pestana J; Larsen CP
    Clin Transplant; 2018 Apr; 32(4):e13225. PubMed ID: 29461660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
    J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of SARS-CoV-2 vaccine with immunosuppressive agents.
    Kamei K; Ogura M; Sato M; Nishi K; Shoji K; Funaki T; Ogimi C; Ito S
    Pediatr Int; 2022 Jan; 64(1):e15331. PubMed ID: 36331234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
    Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
    Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.